New hope for advanced colon cancer: 4-drug combo enters phase 2 trial
NCT ID NCT07446387
First seen Mar 06, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab and chemotherapy as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tumors and how safe it is. About 70 adults aged 18-75 who have not had prior treatment for their advanced cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.